Julio A Lamprea-Montealegre1, A Richey Sharrett2, Kunihiro Matsushita3, Elizabeth Selvin4, Moyses Szklo5, Brad C Astor6. 1. Department of Medicine, University of Maryland School of Medicine, United States. Electronic address: jlamprea@umm.edu. 2. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, United States. Electronic address: rsharret@jhsph.edu. 3. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, United States. Electronic address: kmatsush@jhsph.edu. 4. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, United States. Electronic address: lselvin@jhsph.edu. 5. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, United States. Electronic address: mszklo@jhsph.edu. 6. Department of Medicine, University of Wisconsin School of Medicine and Public Health, United States; Department of Population Health Sciences, University of Wisconsin School of Medicine and Public Health, United States. Electronic address: bcastor@medicine.wisc.edu.
Abstract
BACKGROUND: Chronic kidney disease (CKD) is associated with elevated apolipoprotein B to A-1 ratio (ApoB/A1). It is not known whether these markers are more strongly associated with the risk of coronary heart disease (CHD) in CKD compared to traditionally measured lipids and lipoprotein cholesterol ratios. METHODS: We studied the association of lipids and apolipoproteins including non-HDL-cholesterol to HDL-cholesterol ratio (NonHDLc/HDLc) and ApoB/A1 with incident CHD in 10,137 individuals free of CHD at baseline (visit four) in the Atherosclerosis Risk in Communities (ARIC) study. An estimated glomerular filtration rate of 15 to <60 ml/min/1.73 m(2) based on a cystatin C measurement was used to define CKD (Stage 3-4). Cox proportional hazards regression models were used to determine the association of lipids and apolipoprotein measurements with the risk of CHD in those with and without CKD after adjustment for demographic and known clinical cardiovascular risk factors. RESULTS: CKD was present in 1217 (12%) individuals free of CHD at baseline. The median follow-up time was 11.1 years. A CHD event developed in 498 out of 8920 individuals without CKD (incidence rate: 5.2 events per 1000 person-years) and in 138 out of 1217 individuals with CKD (incidence rate: 12.0 events per 1000 person-years; P < 0.001). Those with CKD had a lower concentration of ApoA1: median (in g/L) and interquartile range (IQR) = 1.40 (1.38-1.42) vs. 1.48 (1.47-1.49) P < 0.001; and a higher ApoB/A1 = 0.75 (0.73-0.77) vs. 0.71 (0.70-0.72) P < 0.001; than those without CKD (eGFR ≥ 60 ml/min/1.73 m(2)). Among individuals with CKD, ApoB/A1 and NonHDLc/HDLc were both associated with the risk of CHD: hazard ratios (HR) and 95% confidence intervals (CI) per one standard deviation increase = 1.22 (1.02-1.46) for ApoB/A1 and 1.30 (1.07-1.57) for NonHDLc/HDLc with no significant differences detected (P for interaction >0.1) when comparing these estimates to those of participants without CKD. CONCLUSIONS: Although CKD is associated with a lower ApoA1 concentration and with a higher ApoB/A1, we found no evidence that these apolipoproteins are more strongly associated with CHD incidence in CKD compared to NonHDLc/HDLc.
BACKGROUND:Chronic kidney disease (CKD) is associated with elevated apolipoprotein B to A-1 ratio (ApoB/A1). It is not known whether these markers are more strongly associated with the risk of coronary heart disease (CHD) in CKD compared to traditionally measured lipids and lipoprotein cholesterol ratios. METHODS: We studied the association of lipids and apolipoproteins including non-HDL-cholesterol to HDL-cholesterol ratio (NonHDLc/HDLc) and ApoB/A1 with incident CHD in 10,137 individuals free of CHD at baseline (visit four) in the Atherosclerosis Risk in Communities (ARIC) study. An estimated glomerular filtration rate of 15 to <60 ml/min/1.73 m(2) based on a cystatin C measurement was used to define CKD (Stage 3-4). Cox proportional hazards regression models were used to determine the association of lipids and apolipoprotein measurements with the risk of CHD in those with and without CKD after adjustment for demographic and known clinical cardiovascular risk factors. RESULTS: CKD was present in 1217 (12%) individuals free of CHD at baseline. The median follow-up time was 11.1 years. A CHD event developed in 498 out of 8920 individuals without CKD (incidence rate: 5.2 events per 1000 person-years) and in 138 out of 1217 individuals with CKD (incidence rate: 12.0 events per 1000 person-years; P < 0.001). Those with CKD had a lower concentration of ApoA1: median (in g/L) and interquartile range (IQR) = 1.40 (1.38-1.42) vs. 1.48 (1.47-1.49) P < 0.001; and a higher ApoB/A1 = 0.75 (0.73-0.77) vs. 0.71 (0.70-0.72) P < 0.001; than those without CKD (eGFR ≥ 60 ml/min/1.73 m(2)). Among individuals with CKD, ApoB/A1 and NonHDLc/HDLc were both associated with the risk of CHD: hazard ratios (HR) and 95% confidence intervals (CI) per one standard deviation increase = 1.22 (1.02-1.46) for ApoB/A1 and 1.30 (1.07-1.57) for NonHDLc/HDLc with no significant differences detected (P for interaction >0.1) when comparing these estimates to those of participants without CKD. CONCLUSIONS: Although CKD is associated with a lower ApoA1 concentration and with a higher ApoB/A1, we found no evidence that these apolipoproteins are more strongly associated with CHD incidence in CKD compared to NonHDLc/HDLc.
Authors: Neris Dincer; Tuncay Dagel; Baris Afsar; Adrian Covic; Alberto Ortiz; Mehmet Kanbay Journal: Int Urol Nephrol Date: 2018-12-05 Impact factor: 2.370
Authors: Archna Bajaj; Scott M Damrauer; Amanda H Anderson; Dawei Xie; Matthew J Budoff; Alan S Go; Jiang He; James P Lash; Akinlolu Ojo; Wendy S Post; Mahboob Rahman; Muredach P Reilly; Danish Saleheen; Raymond R Townsend; Jinbo Chen; Daniel J Rader Journal: Arterioscler Thromb Vasc Biol Date: 2017-08-24 Impact factor: 8.311
Authors: Archna Bajaj; Dawei Xie; Esteban Cedillo-Couvert; Jeanne Charleston; Jing Chen; Rajat Deo; Harold I Feldman; Alan S Go; Jiang He; Edward Horwitz; Radhakrishna Kallem; Mahboob Rahman; Matthew R Weir; Amanda H Anderson; Daniel J Rader Journal: Am J Kidney Dis Date: 2019-01-25 Impact factor: 8.860
Authors: Santosh L Saraf; Xu Zhang; Binal N Shah; Rasha Raslan; Bamidele O Tayo; James P Lash; Nora Franceschini; Victor R Gordeuk Journal: Br J Haematol Date: 2020-11-20 Impact factor: 6.998
Authors: Jacqueline D Wright; Aaron R Folsom; Josef Coresh; A Richey Sharrett; David Couper; Lynne E Wagenknecht; Thomas H Mosley; Christie M Ballantyne; Eric A Boerwinkle; Wayne D Rosamond; Gerardo Heiss Journal: J Am Coll Cardiol Date: 2021-06-15 Impact factor: 27.203